Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients

Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients

Before licensing, ipilimumab was first made available to previously treated advanced melanoma patients through an expanded access programme (EAP) across Europe. We interrogated data from UK EAP patients to inform future clinical practice. Clinicians registered in the UK EAP provided anonymized patie...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron:	S Ahmad, S, Qian, W, Ellis, S, Mason, E, Khattak, M, Gupta, A, Shaw, H, Quinton, A, Kovarikova, J, Thillai, K, Rao, A, Board, R, Nobes, J, Dalgleish, A, Grumett, S, Maraveyas, A, Danson, S, Talbot, T, Harries, M, Marples, M, Plummer, R, Kumar, S, Nathan, P, Middleton, M, Larkin, J, Lorigan, P, Wheater, M, Ottensmeier, C, Corrie, P
Fformat:	Journal article
Iaith:	English
Cyhoeddwyd:	Lippincott, Williams and Wilkins 2015

Eitemau Tebyg

Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: the MELODY study.
gan: Lorigan, P, et al.
Cyhoeddwyd: (2014)

Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
gan: Dalle, S, et al.
Cyhoeddwyd: (2021)

Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab
gan: M. Hardy-Werbin, et al.
Cyhoeddwyd: (2018-02-01)

DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.
gan: Gupta, A, et al.
Cyhoeddwyd: (2014)

DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma
gan: Gupta, A, et al.
Cyhoeddwyd: (2013)

Long-term real-world (RW) outcomes in patients with advanced melanoma (MEL) treated with ipilimumab (IPI) and non-IPI therapies: IMAGE study
gan: Dalle, S, et al.
Cyhoeddwyd: (2019)

Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment
gan: Revicki Dennis A, et al.
Cyhoeddwyd: (2012-06-01)

Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer
gan: Max Hardy-Werbin, et al.
Cyhoeddwyd: (2019-06-01)

Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
gan: Bart Neyns, et al.
Cyhoeddwyd: (2022-07-01)

Retrospective Analysis of Rechallenge with Ipilimumab in Patients with Metastatic Melanoma
gan: A. A. Formozo, et al.
Cyhoeddwyd: (2021-01-01)

Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF Melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial
gan: Urbonas, V, et al.
Cyhoeddwyd: (2018)

Results of combined nivolumab and ipilimumab therapy in patients with cancer
gan: M. A. Lyadova, et al.
Cyhoeddwyd: (2021-12-01)

Real‐world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study
gan: Middleton, M, et al.
Cyhoeddwyd: (2016)

Nivolumab with Ipilimumab in the treatment of refractory hepatocellular carcinoma
gan: M. N. Khagazheeva, et al.
Cyhoeddwyd: (2022-06-01)

Ipilimumab Pharmacotherapy in Patients with Metastatic Melanoma
gan: Joanne M. Jeter, et al.
Cyhoeddwyd: (2012-01-01)

Case Report: Thrombotic-Thrombocytopenic Purpura Following Ipilimumab and Nivolumab Combination Immunotherapy for Metastatic Melanoma
gan: W. J. Mullally, et al.
Cyhoeddwyd: (2022-04-01)

The Predicted Impact of Ipilimumab Usage on Survival in Previously Treated Advanced or Metastatic Melanoma in the UK.
gan: James Larkin, et al.
Cyhoeddwyd: (2015-01-01)

First-line Nivolumab plus Ipilimumab in patients with advanced melanoma previously treated with adjuvant systemic therapy
gan: K. Kisielewska, et al.
Cyhoeddwyd: (2024-01-01)

Durability of response in metastatic melanoma patients after combined treatment with radiation therapy and ipilimumab
gan: Quaovi H Sodji, et al.
Cyhoeddwyd: (2020-05-01)

Panhypopituitarism induced by ipilimumab
gan: Miyu Shiratori, et al.
Cyhoeddwyd: (2020-01-01)

Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).
gan: O'Brien, M, et al.
Cyhoeddwyd: (2013)

IgA Nephropathy Secondary to Ipilimumab Use
gan: Sean C. Dougherty, et al.
Cyhoeddwyd: (2021-11-01)

Comparisons of therapeutic efficacy and safety of ipilimumab plus GM-CSF versus ipilimumab alone in patients with cancer: a meta-analysis of outcomes
gan: Chen P, et al.
Cyhoeddwyd: (2018-07-01)

Acute visual loss after ipilimumab treatment for metastatic melanoma
gan: Melissa A. Wilson, et al.
Cyhoeddwyd: (2016-11-01)

Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial
gan: Weber, J, et al.
Cyhoeddwyd: (2019)

A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome
gan: Ian M. Bouligny, et al.
Cyhoeddwyd: (2025-02-01)

IPILIMUMAB IN THERAPY OF METASTATIC MELANOMA
gan: I. V. SAMOILENKO, et al.
Cyhoeddwyd: (2016-12-01)

Ipilimumab-Induced Neutropenia in Melanoma
gan: Makiko Ban-Hoefen MD, et al.
Cyhoeddwyd: (2016-08-01)

Ipilimumab induced digital vasculitis
gan: Amrita Padda, et al.
Cyhoeddwyd: (2018-02-01)

Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial
gan: Celeste Lebbe, et al.
Cyhoeddwyd: (2023-05-01)

Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab
gan: William L Redmond, et al.
Cyhoeddwyd: (2021-10-01)

Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab
gan: Alexandre Reuben, et al.
Cyhoeddwyd: (2017-12-01)

25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial
gan: Lipplaa, A, et al.
Cyhoeddwyd: (2018)

Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date
gan: Remon J, et al.
Cyhoeddwyd: (2019-05-01)

Feasibility and efficacy of preoperative ipilimumab/nivolumab in loco-regionally advanced urothelial cancer of the bladder (NABUCCO)
gan: B.W.G. Van Rhijn, et al.
Cyhoeddwyd: (2020-07-01)

Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine.
gan: Dangoor, A, et al.
Cyhoeddwyd: (2010)

Ipilimumab and nivolumab in uveal melanoma: report on toxicity and treatment intensity
gan: A. Ciernik, et al.
Cyhoeddwyd: (2024-01-01)

Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis
gan: Priscilla K. Brastianos, et al.
Cyhoeddwyd: (2021-10-01)

Engineered ipilimumab variants that bind human and mouse CTLA-4
gan: Brett Robison, et al.
Cyhoeddwyd: (2025-12-01)

Pre-radiation Nivolumab plus ipilimumab in patients with newly diagnosed high-grade gliomas
gan: Santosh Kesari, et al.
Cyhoeddwyd: (2024-12-01)